TD Cowen lowered the firm’s price target on GeneDx (WGS) to $110 from $135 and keeps a Buy rating on the shares. The firm noted the shares fell after reporting better than expected results and raising guidance. The TAM is largeand barely penetrated, execution has been solid, NICU ramp driving volumes is logical, and price/margins beat and Cowen sees upside.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx price target lowered to $100 from $115 at BTIG
- GeneDx price target lowered to $78 from $105 at Wells Fargo
- GeneDx Reports Strong Q1 2025 Growth and Expansion Plans
- GeneDx Holdings Corp. Reports Strong Earnings and Strategic Growth
- GeneDx Holdings: Strong Growth Potential and Strategic Acquisitions Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue